Management of Nausea and Vomiting Quiz

Ondansetron is a serotonin antagonist that helps alleviate chemotherapy-induced nausea and vomiting.

Antihistamines target Histamine H1 receptors to mitigate motion sickness-induced nausea and vomiting.

QT prolongation is a potential side effect of ondansetron, a serotonin antagonist.

The use of regional anesthesia is not typically associated with an increased risk of postoperative nausea and vomiting (PONV).

Common adverse effects of scopolamine transdermal patches for motion sickness prevention include dry mouth, blurred vision, and drowsiness.

The doxylamine-pyridoxine combination is recommended as the first-line treatment for nausea and vomiting in pregnancy (NVP).

Metoclopramide acts as a dopamine receptor antagonist, enhancing gastrointestinal motility.

Hypertension is not a typical side effect of serotonin antagonists used for nausea and vomiting.

Doxylamine and pyridoxine combination is the recommended first-line treatment for morning sickness in pregnant women.

Ondansetron is considered safe for use in children as an antiemetic medication.

Ginger exerts antiemetic effects by inhibiting serotonin in the GI tract and central nervous system.

Metoclopramide's primary action is to enhance gastrointestinal motility in the management of nausea and vomiting.

Dexamethasone has anti-inflammatory properties that may help reduce nausea in the management of nausea and vomiting.

Acupuncture or acupressure, involving electrical stimulation, is a non-pharmacological intervention for nausea and vomiting.

NK1 receptor antagonists prevent the binding of substance P to NK1 receptors in the brain, thus preventing nausea and vomiting.

Metoclopramide can lead to extrapyramidal symptoms due to its dopamine receptor antagonism in the management of nausea and vomiting.

Increased physical activity is not a typically recommended non-pharmacological intervention for nausea and vomiting in palliative care.

Corticosteroids enhance antiemetic effects in chemotherapy-induced nausea and vomiting, but the exact mechanism is unknown.

Combination therapy with an NK1 receptor antagonist and a glucocorticoid is often considered for refractory nausea and vomiting.

The primary concern with scopolamine transdermal patches is the risk of anticholinergic side effects.

NK1 receptor antagonists are specifically effective for delayed chemotherapy-induced nausea and vomiting.

Preoperative fasting for 12 hours is not a recommended approach for the management of postoperative nausea and vomiting.

Erythromycin acts as a motilin receptor agonist, enhancing gastric emptying in patients with nausea and vomiting due to gastric stasis.

NK1 receptor antagonists are not typically used to manage anticipatory nausea and vomiting in patients undergoing chemotherapy.

Using a combination of antiemetic agents provides the benefit of targeting different pathways involved in the vomiting reflex.